Evaluation of Effectiveness of Oral and Vaginal Misoprostol Administration for Cervical Ripening in Women Before Operative Hysteroscopy

Evaluation of Effectiveness of Oral and Vaginal Misoprostol Administration for Cervical Ripening in Women Before Operative Hysteroscopy: A Double-Blind Randomized Placebo Controlled Clinical Trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220102053602N1

Enrollment

126

Registered

2022-03-16

Start date

2022-04-04

Completion date

Unknown

Last updated

2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Ripening. Abnormal uterine and vaginal bleeding, unspecified

Interventions

Intervention 1: Intervention group: Misoprostol 400 micrograms tablets vaginally (2 pieces 200 micrograms, Samisaz pharmaceutical company, Iran ) and B6 tablets orally (2 pieces, Aminpharma company,

Eligibility

Sex/Gender

Female

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Based on the indications for hysteroscopy

Exclusion criteria

Exclusion criteria: Contraindications for anti-prostaglandin drugs (asthma, or glaucoma) Women who are contraindicated for hysteroscopy (pregnancy, inflammatory bowel disease, malignancy)

Design outcomes

Primary

Measure	Time frame
Cervical Ripening. Timepoint: 12 Hours. Method of measurement: Hegar dilator.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Atefeh Mehralitabar Firoozjah

Gorgan University of Medical Sciences

atefehfiroz@yahoo.com+98 17 3220 2565

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026